Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
Recruiting in Palo Alto (17 mi)
+92 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Takeda
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Research Team
MD
Medical Director
Principal Investigator
Takeda
Eligibility Criteria
Inclusion Criteria
Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D).
Treatment Details
Interventions
- Ilaprazole (Proton Pump Inhibitor)
- Lansoprazole (Proton Pump Inhibitor)
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Group I: Ilaprazole 5 mg QDExperimental Treatment1 Intervention
Group II: Ilaprazole 40 mg QDExperimental Treatment1 Intervention
Group III: Ilaprazole 20 mg QDExperimental Treatment1 Intervention
Group IV: Lansoprazole 30 mg QDActive Control1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
NCT00471094Tempe, AZ
NCT00471094Chandler, AZ
NCT00471094Phoenix, AZ
NCT00471094Tucson, AZ
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Takeda
Lead Sponsor
Trials
1255
Patients Recruited
4,219,000+